Smith & Nephew, Inc.
smith-nephew.comTotal trials
131
Active
21
Phase 3
0
Total enrollment
17,692
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Iontophoresis and tube placement | — | — | — | — | — | 1 |
Next readouts
- 2025-03-30
Top conditions
- Osteoarthritis12
- Rheumatoid Arthritis8
- Pressure Ulcer6
- Knee6
- Wounds and Injuries5
- Arthroplasty5
- Replacement5
- Degenerative Arthritis4
Frequently asked questions about Smith & Nephew, Inc.
- How many clinical trials does Smith & Nephew, Inc. have on ClinicalTrials.gov?
- Smith & Nephew, Inc. is listed as the lead sponsor on 131 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Smith & Nephew, Inc.'s trials are in Phase 3?
- 0 of Smith & Nephew, Inc.'s trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Smith & Nephew, Inc. focus on?
- Smith & Nephew, Inc.'s most-studied conditions on ClinicalTrials.gov are Osteoarthritis, Rheumatoid Arthritis, Pressure Ulcer, Knee, Wounds and Injuries.
- When are Smith & Nephew, Inc.'s next clinical trial readouts?
- Smith & Nephew, Inc. has 1 upcoming primary-completion readout tracked here; the soonest is “Evaluation of Outcomes Following In-office Tympanostomy Using the Tula® System: a Prospective, Multi-center Registry”, expected around 2025-03-30.